Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05810350 2023-04-13

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Phase 2 Unknown

40 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04944069 2021-06-29

ATTRACT

Phase NA Unknown

69 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04833205 2021-04-20

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Phase 2 Unknown

30 enrolled

CNSThoracic

Lung Neoplasms, Meningeal Carcinomatosis

NCT04425681 2020-06-11

OWBLM

Phase 2 Unknown

20 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04148898 2019-11-04

OWONBNSCLCLM

Phase 2 Unknown

80 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02607605 2017-10-26

ctDNA

Unknown

10 enrolled

CNSThoracic

Lung Neoplasms, Meningeal Carcinomatosis

NCT02803619 2016-06-17

A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis

Unknown

60 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Clinical Trials

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

ATTRACT

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

OWBLM

OWONBNSCLCLM

ctDNA

A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis